AddLife AB operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares AddLife AB with three other
miscellaneous service companies in Europe:
Basilea Pharmaceutica Limited
sales of 114.79 million Swiss Francs [US$117.49 million]
GW Pharmaceuticals PLC
of UNITED KINGDOM
(£243.39 million [US$289.41 million]
of which 100%
was Novel Therapeutics), and
Clinigen Group PLC
based in UNITED KINGDOM
(£456.90 million [US$543.28 million]
of which 45%
was Unlicensed Medicines).
AddLife AB reported sales of SEK 3.48 billion (US$343.90 million)
December of 2019.
increase of 40.2%
versus 2018, when the company's sales were SEK 2.48 billion.
Sales at AddLife AB have increased during each of the previous five years
(and since 2014, sales have increased a total of 254%).